Table 3 The relationship of recurrence and clinicopathological parameters in stage III GC

Preoperative CEA(ng/mL)

7.317

0.007

≤ 5

212

50(23.6%)

162(76.4%)

> 5

90

35(38.9%)

55(61.1%)

Preoperative CA19-9(U/mL)

16.381

< 0.001

≤ 35

235

53(22.6%)

182(77.4%)

> 35

67

32(47.8%)

35(52.2%)

Preoperative CA72-4(U/mL)

1.739

0.187

≤ 6.9

242

64(26.4%)

178(73.6%)

> 6.9

60

21(35.0%)

39(65.0%)

Age(years)

1.715

0.190

< 60

80

18(22.5%)

62(77.5%)

≥ 60

222

67(30.2%)

155(69.8%)

Sex

2.136

0.144

Female

82

18(22.0%)

64(78.0%)

Male

220

67(30.5%)

153(69.5%)

Tumor location

6.462

0.091

Upper

81

21(25.9%)

60(74.1%)

Middle

54

21(38.9%)

33(61.1%)

Lower

147

41(27.9%)

106(72.1%)

Other

20

2*(20.0%)

18(80.0%)

Tumor size (cm)

1.326

0.249

< 5

151

38(25.2%)

113(74.8%)

≥ 5

151

47(31.1%)

104(68.9%)

Depth of invasion

0.254

0.614

T2-T3

202

55(27.2%)

147(72.8%)

T4

100

30(30.0%)

70(70.0%)

Lymph node metastasis

6.697

0.010

N0-N1

52

7(13.5%)

45(86.5%)

N2-N3

250

78(31.2%)

172(68.8%)

Vascular invasion

3.537

0.060

Yes

234

72(30.8%)

162(69.2%)

No

68

13(19.1%)

55(80.9%)

Nerve invasion

0.241

0.624

Yes

247

71(28.7%)

176(71.3%)

No

55

14(25.5%)

41(74.5%)

Degree of differentiation

3.969

0.046

Moderately

31

4*(12.9%)

27(87.1%)

Poorly

271

81(29.9%)

190(70.1%)

Postoperative adjuvant chemotherapy

2.062

0.151

Yes

140

45(32.1%)

95(67.9%)

No

162

40(24.7%)

122(75.3%)

Postoperative CEA(ng/mL)

20.374

< 0.001

≤ 5

228

49(21.5%)

179(78.5%)

> 5

74

36(48.6%)

38(51.4%)

Postoperative CA19-9(U/mL)

35.794

< 0.001

≤ 35

260

57(21.9%)

203(78.1%)

> 35

42

28(66.7%)

14(33.3%)

Postoperative CA72-4(U/mL)

26.349

< 0.001

≤ 6.9

264

61(23.1%)

203(76.9%)

> 6.9

38

24(63.2%)

14(36.8%)